- Home
- REPL vs CPAC Comparison
REPL vs CPAC Comparison
Compare REPL & CPAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REPL
- CPAC
- Stock Information
- Founded
- REPL 2015
- CPAC 1949
- Country
- REPL United States
- CPAC Peru
- Employees
- REPL N/A
- CPAC N/A
- Industry
- REPL Biotechnology: Pharmaceutical Preparations
- CPAC Building Materials
- Sector
- REPL Health Care
- CPAC Industrials
- Exchange
- REPL Nasdaq
- CPAC Nasdaq
- Market Cap
- REPL 547.0M
- CPAC 580.5M
- IPO Year
- REPL 2018
- CPAC 2012
- Fundamental
- Price
- REPL $10.07
- CPAC $7.27
- Analyst Decision
- REPL Buy
- CPAC Hold
- Analyst Count
- REPL 9
- CPAC 1
- Target Price
- REPL $10.88
- CPAC $6.40
- AVG Volume (30 Days)
- REPL 8.8M
- CPAC 8.1K
- Earning Date
- REPL 11-07-2025
- CPAC 10-28-2025
- Dividend Yield
- REPL N/A
- CPAC 6.89%
- EPS Growth
- REPL N/A
- CPAC 26.68
- EPS
- REPL N/A
- CPAC 0.14
- Revenue
- REPL N/A
- CPAC $572,828,408.00
- Revenue This Year
- REPL N/A
- CPAC N/A
- Revenue Next Year
- REPL N/A
- CPAC N/A
- P/E Ratio
- REPL N/A
- CPAC $10.10
- Revenue Growth
- REPL N/A
- CPAC 3.37
- 52 Week Low
- REPL $2.68
- CPAC $5.10
- 52 Week High
- REPL $17.00
- CPAC $7.50
- Technical
- Relative Strength Index (RSI)
- REPL 75.32
- CPAC 57.47
- Support Level
- REPL $7.69
- CPAC $7.13
- Resistance Level
- REPL $10.85
- CPAC $7.50
- Average True Range (ATR)
- REPL 0.67
- CPAC 0.18
- MACD
- REPL 0.48
- CPAC -0.01
- Stochastic Oscillator
- REPL 88.10
- CPAC 41.77
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
About CPAC Cementos Pacasmayo S.A.A. (Each representing five)
Cementos Pacasmayo SAA is a Peruvian cement company that produces, distributes, and sells cement and cement-related materials, such as concrete blocks and ready-mix concrete. The company's products are used in construction. It also produces and sells quicklime for use in mining operations. The company sells its products mainly in the northern part of Peru. It owns three cement production and transportation facilities. Its flagship Pacasmayo facility is located in the northwest region of Peru, while its new cement plant in Piura and smaller Rioja facility are located in the northeast region of Peru.